Previous 10 | Next 10 |
FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old PR Newswire - Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, chi...
A committee of the European Medicines Agency (EMA) recommended the approval of PTC Therapeutics' (NASDAQ:PTCT) one time gene therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults. The company said Upstaza (eladocagene exuparvovec)...
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency PR Newswire – First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – ...
Start Time: 16:30 End Time: 17:36 PTC Therapeutics, Inc. (PTCT) Q1 2022 Earnings Conference Call May 03, 2022, 16:30 PM ET Company Participants Stuart Peltz - Founder and CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Kylie O’Keefe - SVP, Global Commerci...
PTC Therapeutics press release (NASDAQ:PTCT): Q1 GAAP EPS of -$1.78 misses by $0.27. Revenue of $149M (+26.3% Y/Y) beats by $2.1M. For further details see: PTC Therapeutics GAAP EPS of -$1.78 misses by $0.27, revenue of $149M beats by $2.1M
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results PR Newswire - $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease &...
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast confere...
Biopharmaceutical company PTC Therapeutics (NASDAQ:PTCT) on Thursday said it has completed procedural meetings for its gene therapy treatment for (AADC) deficiency with the European Union drug regulator's Committee for Advanced Therapies (CAT). The CAT will provide its opinion for adoption of...
PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program PR Newswire - CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (...
PTC Therapeutics has been cooperating with Roche since 2011. Evrysdi's sales were CHF 206 million in the fourth quarter of 2021, up 338% from the fourth quarter of 2020. PTC Therapeutics management expects the company's revenue of $700-750 million in 2022, which is 34.6% more than...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....